Jaguar Health Reports Revenue Surge to $21.5M, Operating Income Turnaround in Latest 10-Q

Jaguar Health, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated total revenue of $21.5 million for the first half of 2026, a substantial increase from $5.2 million in the same period of 2025, primarily driven by a $19 million increase in license revenue following a licensing agreement with Woodward Specialty LLC. However, product revenue saw a decline, dropping to $2.4 million from $5.1 million year-over-year, largely due to reduced sales of its human health product, Mytesi, as distribution transitioned to Woodward.

Operating expenses decreased to $18.9 million in the first half of 2026 from $22.6 million in the prior year, reflecting a strategic reduction in sales and marketing costs after the licensing agreement. The company reported an operating income of $2.6 million, a notable turnaround from an operating loss of $17.4 million in the first half of 2025. Despite this improvement, Jaguar recorded a net loss of $4.1 million for the six months ended June 30, 2026, compared to a net loss of $21.2 million for the same period in 2025.

In terms of operational metrics, Jaguar's cash position improved significantly, with cash and restricted cash totaling $6.6 million as of June 30, 2026, compared to $2.2 million at the end of 2025. The company’s total liabilities decreased to $29.3 million from $57 million, primarily due to the repayment of debt and the restructuring of financial instruments. The company also reported a total stockholders' equity of $4.9 million, a recovery from a deficit of $18.7 million at the end of 2025.

Strategically, Jaguar has made several organizational changes, including the establishment of JAGX Holdings, a subsidiary formed to manage cash collateral for its obligations under a note purchase agreement. The company is also focusing on expanding its product offerings, with plans to launch Neonorm Dog, a new product aimed at supporting gastrointestinal health in dogs. Additionally, Jaguar is advancing its clinical trials for crofelemer, targeting conditions such as microvillus inclusion disease and short bowel syndrome, which are expected to enhance its market position in the gastrointestinal treatment space.

Looking ahead, Jaguar Health anticipates continued investment in research and development, particularly in its human health segment, while also seeking additional financing to support its operations. The company remains cautious about its liquidity, noting that while recent agreements have improved its cash position, it still faces challenges in generating sufficient revenue to sustain its operations long-term.